Scholarlink

Background <p>Fusion-positive rhabdomyosarcoma (FP-RMS) is driven by the oncogenic transcription factor PAX3-FOXO1 and is associated with poor clinical outcome. The histone demethylase KDM4B has been implicated in sustaining PAX3-FOXO1-dependent transcriptional programs, but the epigenetic regulatory mechanisms supporting this network remain incompletely characterized.</p> Methods <p>We employed a deep learning-based drug discovery strategy and identified a novel small-molecule, Compound <b>01</b>. Functional and mechanistic analyses were then performed to delineate cooperative interactions among KDM4B, KDM5A, and PAX3-FOXO1, and to evaluate the impact of pharmacological perturbation on the stability of this transcriptional network in FP-RMS models.</p> Results <p>In this study, we identified Compound <b>01</b> with dual activity against KDM4B and KDM5A that triggers proteasome-dependent loss of both proteins. Mechanistically, we uncover a reciprocal stabilization loop in which KDM4B, KDM5A, and PAX3–FOXO1 reinforce each other to sustain the PAX3–FOXO1 transcriptional state. Pharmacological disruption of this axis by Compound <b>01</b> collapses the PAX3–FOXO1-driven oncogenic transcriptional program, suppresses key downstream targets, and markedly impairs FP-RMS cell proliferation and metastatic potential.</p> Conclusion <p>These findings identify KDM5A as a critical epigenetic partner of the PAX3–FOXO1 network and establish dual KDM4B/KDM5A targeting as a strategy to destabilize PAX3–FOXO1 transcriptional circuitry in FP-RMS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual inhibition of KDM4B and KDM5A disassembles the PAX3-FOXO1 transcriptional program in fusion-positive rhabdomyosarcoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Junhong Yuan,
  • Qilei Han,
  • Pengxuan Ren,
  • Fang Bai,
  • Xianglei Zhang,
  • Kai Li

摘要

Background

Fusion-positive rhabdomyosarcoma (FP-RMS) is driven by the oncogenic transcription factor PAX3-FOXO1 and is associated with poor clinical outcome. The histone demethylase KDM4B has been implicated in sustaining PAX3-FOXO1-dependent transcriptional programs, but the epigenetic regulatory mechanisms supporting this network remain incompletely characterized.

Methods

We employed a deep learning-based drug discovery strategy and identified a novel small-molecule, Compound 01. Functional and mechanistic analyses were then performed to delineate cooperative interactions among KDM4B, KDM5A, and PAX3-FOXO1, and to evaluate the impact of pharmacological perturbation on the stability of this transcriptional network in FP-RMS models.

Results

In this study, we identified Compound 01 with dual activity against KDM4B and KDM5A that triggers proteasome-dependent loss of both proteins. Mechanistically, we uncover a reciprocal stabilization loop in which KDM4B, KDM5A, and PAX3–FOXO1 reinforce each other to sustain the PAX3–FOXO1 transcriptional state. Pharmacological disruption of this axis by Compound 01 collapses the PAX3–FOXO1-driven oncogenic transcriptional program, suppresses key downstream targets, and markedly impairs FP-RMS cell proliferation and metastatic potential.

Conclusion

These findings identify KDM5A as a critical epigenetic partner of the PAX3–FOXO1 network and establish dual KDM4B/KDM5A targeting as a strategy to destabilize PAX3–FOXO1 transcriptional circuitry in FP-RMS.